- Iovance Biotherapeutics has lost more than two-thirds its share value since January 2021 as a delayed BLA filing and the resignation of the company’s CEO in May have added uncertainty.
- Owing to a potency assay issue with its lead asset lifileucel, there has also been little new data on it for the treatment of metastatic melanoma and metastatic cervical cancer.
- With a potential blockbuster therapy for two solid tumor cancers and excellent efficacy results to date, Iovance merited a deeper dive.
- A full investment analysis follows in the paragraphs below.
For further details see:
Iovance Biotherapeutics: Uncertainty And Opportunity